Yun C H, Shimada T, Guengerich F P
Department of Biochemistry, Vanderbilt University School of Medicine, Nashville, Tennessee 37232-0146.
Cancer Res. 1992 Apr 1;52(7):1868-74.
The major oxidation product of the classic polycyclic hydrocarbon carcinogen benzo(a)pyrene [B(a)P] is 3-hydroxy B(a)P. Numerous studies have been concerned with the measurement of B(a)P 3-hydroxylation activity in experimental animals and human tissues. Although human liver is the main site of this reaction, systematic studies had not been carried out to define the roles of individual cytochrome P-450 (P-450) enzymes involved. Purified human P4502C8 and P4503A4 showed appreciable catalytic activity; purified human P4501A2 and yeast recombinant (human) P4502C9 and P4502C10 had less activity. No B(a)P 3-hydroxylation activity was observed with purified human P4502A6, P4502D6, P45602E1, or P4502CMP. When microsomes prepared from different human liver samples were compared, B(a)P 3-hydroxylation activity was well correlated with nifedipine oxidation (a P4503A4 marker) but not markers of other P-450s, including tolbutamide hydroxylation (P4502C9 and 2C10), chlorzoxazone 6-hydroxylation (P4502E1), (S)-mephenytoin 4'-hydroxylation (P4502CMP), and coumarin 7-hydroxylation (P4502A6). In three of the liver microsomal samples with relatively high B(a)P 3-hydroxylation activity, immunoinhibition was observed with anti-P4503A greater than anti-P4502C (and no inhibition with several other antibodies). The selective chemical inhibitors gestodene and troleandomycin (P4503A enzymes) and sulfaphenazole (P4502C enzymes) reduced the B(a)P 3-hydroxylation activity of the more active microsomal preparations to rates seen in the preparations with low activity. This residual activity (and most of the activity in the low activity samples) was refractory to all of the chemical inhibitors and antibodies. The addition of 7,8-benzoflavone dramatically stimulated B(a)P 3-hydroxylation in all of the microsomal samples (and also stimulated purified P4503A4), arguing against an important role for P4501A1 or P4501A2. We conclude that roles of human P-450 enzymes for B(a)P 3-hydroxylation follow the order P4503A4 greater than or equal to P4502C8 greater than P4502C9/10 in human liver and that the other P-450s examined here do not have major roles. P4502C8 and P4502CMP (but not P4503A4) were found to activate B(a)P to products genotoxic in Salmonella typhimurium; this pathway would appear to involve products other than 3-hydroxy B(a)P and B(a)P 7,8-dihydrodiols.
经典多环烃致癌物苯并(a)芘[B(a)P]的主要氧化产物是3-羟基B(a)P。众多研究关注于实验动物和人体组织中B(a)P 3-羟化活性的测定。尽管人类肝脏是该反应的主要场所,但尚未开展系统性研究来确定所涉及的各个细胞色素P-450(P-450)酶的作用。纯化的人P4502C8和P4503A4表现出明显的催化活性;纯化的人P4501A2以及酵母重组(人)P4502C9和P4502C10活性较低。纯化的人P4502A6、P4502D6、P45602E1或P4502CMP未观察到B(a)P 3-羟化活性。当比较从不同人肝脏样本制备的微粒体时,B(a)P 3-羟化活性与硝苯地平氧化(一种P4503A4标志物)密切相关,但与其他P-450的标志物无关,包括甲苯磺丁脲羟化(P4502C9和2C10)、氯唑沙宗6-羟化(P4502E1)、(S)-美芬妥英4'-羟化(P4502CMP)和香豆素7-羟化(P4502A6)。在三个具有相对较高B(a)P 3-羟化活性的肝脏微粒体样本中,观察到抗P4503A的免疫抑制作用大于抗P4502C(而其他几种抗体无抑制作用)。选择性化学抑制剂孕二烯酮和三乙酰竹桃霉素(P4503A酶)以及磺胺苯吡唑(P4502C酶)将活性较高的微粒体制剂的B(a)P 3-羟化活性降低至活性较低制剂中的水平。这种残余活性(以及低活性样本中的大部分活性)对所有化学抑制剂和抗体均无反应。添加7,8-苯并黄酮可显著刺激所有微粒体样本中的B(a)P 3-羟化(也刺激纯化的P4503A4),这表明P4501A1或P4501A2不起重要作用。我们得出结论,人肝脏中参与B(a)P 3-羟化的P-450酶的作用顺序为P4503A4≥P4502C8>P4502C9/10,此处检测的其他P-450不起主要作用。发现P4502C8和P4502CMP(但不是P4503A4)可将B(a)P激活为在鼠伤寒沙门氏菌中具有遗传毒性的产物;该途径似乎涉及除3-羟基B(a)P和B(a)P 7,8-二氢二醇以外的产物。